In a report released today, Chad Messer from Needham assigned a Buy rating to G1 Therapeutics (GTHX), with a price target of $74.00. The company’s shares closed last Wednesday at $24.21.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 15.5% and a 54.5% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Currently, the analyst consensus on G1 Therapeutics is a Strong Buy with an average price target of $58.50, implying a 133.0% upside from current levels. In a report issued on June 26, Roth Capital also initiated coverage with a Buy rating on the stock with a $55.00 price target.
See today’s analyst top recommended stocks >>
Based on G1 Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $31.02 million. In comparison, last year the company had a GAAP net loss of $23.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
